Attoquant Diagnostics GmbH
Attoquant Diagnostics was founded in 2012 as a spin-off of Apeiron Biologics AG in Vienna. After the foundation of the company, the RAS Fingerprint, a worldwide unique research tool for the molecular characterization of the renin-angiotensin system, was further developed to a clinical biomarker for hypertension profiling: The RAAS Triple-A test.
With the support of our international research network, clinical validation was performed and published in high ranged research journals. As a next step and scale up strategy, a diagnostic kit will be produced and sold, that will finally be supplemented with the implementation of an e-Health platform automatically generating the clinical interpretation of test results.
RAAS Triple-A testing is based on a clinical high-throughput mass-spectrometry assay for simultaneous quantification of Angiotensin I, Angiotensin II and Aldosterone in standard serum by RAAS equilibrium analysis ( => IP). Equilibrium angiotensin and aldosterone levels are used to calculate markers for renin-activity (PRA-S), angiotensin-converting-enzyme activity (ACE-S) and adrenal function (AA2-Ratio).